Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Roche's Genentech and Halozyme have received FDA approval for Tecentriq Hybreza, the first subcutaneous PD-(L)1 cancer immunotherapy. This new option offers faster treatment times and maintains the safety and efficacy of the intravenous version.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 7:15 am

Roche shares are experiencing a decline in trading following the release of weight loss data.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 7:52 pm

Roche's CT-996 Phase 1 trial for an obesity pill showed promising results, with the best-performing cohort achieving a 7.3% weight loss over four weeks, compared to a 1.2% loss in the placebo group. The placebo-adjusted average weight loss was 6.1% in one of the active cohorts.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:49 pm

BofA Securities has upgraded Fulcrum Therapeutics (FULC) from Underperform to Neutral, increasing the price target from $5 to $10, ahead of the phase 3 readout for losmapimod in treating FSHD. The study's success is debated due to a new endpoint, RWS, and potential competition from Avidity Biosciences and Roche.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 6:28 pm

HC Wainwright initiated coverage on Enliven Therapeutics (NASDAQ:ELVN), highlighting its promising leukemia candidate ELVN-001, which could challenge existing treatments from Pfizer and AstraZeneca. The analyst gave a Buy rating with a $37 price target, noting potential peak sales of over $500 million.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 6:05 pm

Roche is enhancing its digital pathology platform by integrating over 20 AI algorithms from eight new collaborators. This move aims to improve cancer diagnostics and personalized healthcare through AI-driven insights.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:16 am

Poseida Therapeutics is set to present new clinical data from its Phase 1 study of the allogeneic CAR-T therapy P-BCMA-ALLO1 at the International Myeloma Society Annual Meeting. The initiation of a Phase 1b trial has generated a $20 million payment from Roche.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 1:14 pm

Moderna and BioNTech are focusing on personalized cancer vaccines using mRNA technology to counteract declining COVID-19 vaccine sales. Despite promising developments, high costs and production challenges raise concerns about scalability and affordability.

Portfolio Pulse from Vandana Singh

August 29, 2024 | 4:01 pm

Labcorp and Roche are increasing their mpox testing capabilities in response to a new virus strain. Labcorp can scale up from 500 to 25,000 tests monthly, while Roche is leveraging its HIV testing infrastructure. Quest Diagnostics and Abbott Laboratories are also involved in mpox testing.

Portfolio Pulse from Vandana Singh

August 26, 2024 | 5:36 pm

Roche missed out on acquiring a potential blockbuster weight-loss drug, orforglipron, which Eli Lilly acquired for $50 million and is projected to generate up to $14 billion annually by 2032. Roche's cautious approach, influenced by past setbacks, led to this missed opportunity. Roche re-entered the obesity market in 2023 but is expected to lag behind competitors like Eli Lilly and Novo Nordisk.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.